United Therapeutics Corporation Earnings Recaps
Q3 2025
Oct 29, 2025
United Therapeutics Corporation reported a record revenue of $800 million for Q3 2025, reflecting a 7% year-over-year growth, driven by strong demand for Tyvaso and Orenitram and significant advancements in its clinical pipeline.
Key takeaways
- Fully enrolled three Phase III trials, achieving best-ever results for pulmonary fibrosis, indicating strong potential to expand patient treatment.
- Launched new Tyvaso DPI 80-microgram cartridges to enhance dosing convenience and capture additional market share in the pulmonary hypertension space.
- Significant progress in securing favorable payer coverage decisions, reinforcing Tyvaso DPI's competitive positioning in the market.
- Confidently projecting a $4 billion revenue run rate by 2027, backed by ongoing product innovations and market demand.
Q2 2025
Aug 1, 2025
United Therapeutics Corporation reported robust earnings with a record revenue of $799 million, marking the 12th consecutive quarter of double-digit growth driven by strong performance from its Tyvaso portfolio and a promising pipeline of innovative therapies.
Key takeaways
- Achieved total revenue of $799 million, reflecting a 12% year-over-year increase.
- Tyvaso DPI revenues reached a record $315 million, representing 22% growth compared to Q2 2024.
- Strong shipment levels for Tyvaso DPI and overall enhanced market dynamics contribute to sustained demand.
- Key upcoming clinical milestones include results from TETON 2 and progress in the EXPAND - UKidney study.
- Board authorized a share repurchase program of up to $1 billion, reflecting confidence in future growth and shareholder value.